Ketorolac tromethamine 0.4%; oph soln; contains benzalkonium chloride. Do not administer while wearing contacts. Risk of contamination (avoid contact with tip of the bottle). Bleeding tendencies.
Despite the withdrawal of one topical ophthalmic nonsteroidal anti-inflammatory drug (NSAID) from the market, many surgeons continue to use others in the class to prevent inflammation after cataract ...
Please provide your email address to receive an email when new articles are posted on . The area of ocular anti-infective treatment continues to advance, with many of the major pharmaceutical ...
Allergan Inc., the Irvine drug maker, said Thursday that a federal appeals court upheld an earlier ruling protecting its Acular eye drug patent from generics. Allergan said that the U.S. Court of ...
DETROIT, Nov. 6 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug ...
WASHINGTON -- Allergan Inc. said Tuesday that it is cooperating with an investigation by the Federal Trade Commission into competition for its Acular drug used after laser eye surgery. In its ...
A federal judge in San Francisco on Wednesday upheld Allergan Inc.’s patent for its top-selling eye drug Acular, blocking Apotex Inc. from selling a competing product. The ruling may help Allergan in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results